turoctocog alfa

(redirected from Novoeight)

turoctocog alfa

(too-rok-to-cogal–fa) ,


(trade name),

Antihemophilic factor (recombinant)

(trade name)


Therapeutic: hemostatic agents
Pharmacologic: clotting factor replacements
Pregnancy Category: C


Prevention/control of bleeding in patients with hemphilia A


Replaces deficient factor VIII in hemophilia A.
Recombinant product is synthesized in genetically engineered Chinese hamster ovary cell line.

Therapeutic effects

Decreased incidence and severity of bleeding and sequelae of bleeding in hemophilia A


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: Used up in clotting process.
Half-life: Adults—11–12 hr ; children—7.7–10 hr

Time/action profile (effect on clotting)

IVwithin hrend of infusion8–24 (treatment), 2–3 days (prophylaxis)


Contraindicated in: Life-threatening hypersensitivity to turoctcog alfa or any of its components, including hamster protein.
Use Cautiously in: Obstetric: Use during pregnancy only if clearly needed; Lactation: Use only if clearly indicated; Pediatric: Clearance in more rapid in children (↑ dose or more frequent dosing may be necessary)

Adverse Reactions/Side Effects


  • ↑ liver enzymes


  • injection site reactions


  • hypersensitivity reactions including anaphylaxis
  • fever
  • presence of activity-neutralizing antibodies


Drug-Drug interaction

Concurrent use of any drugs that ↑ increase bleeding risk including anticoagulantsantiplatelet agentsaspirinNSAIDs or thrombolytics is contraindicated.


General dosing
Intravenous (Adults and Children) General dosing—Dose required (IU) = body weight (kg) x Desired Factor VIII increase (IU/dL or % normal) x 0.5 (IU/kg per IU/dL)
Control/prevention of bleeding episodes
Intravenous (Adults and Children) Minor bleeding (early hemarthrosis, minor muscle or oral bleeding)—20–40% of normal Factor VIII level required every 12–24 hr for at least one day until resolution of bleeding, Moderate bleeding (muscle bleeding, bleeding into the oral cavity, mild head trauma)—30–60% of normal Factor VIII level required every 12–24 hr until pain/disability resolves (3–4 days), Major bleeding (life/limb–threatening hemorrhage, GI bleeding, intracranial/intra-abdominal/intrathoracic bleeding, fractures)—60–100% of normal Factor VIII level required every 8–24 hr until resolution of bleeding (7–10 days)
Perioperative management
Intravenous (Adults and Children) Minor procedures (including tooth extraction)—30–60 % of normal Factor VIII level required every 24 hr for one day until healing achieved; Major procedures—80–100 % of normal Factor VIII level required every 8–24 hr pre- and post-operative until adequate wound healing achieved then continue for 7–10 days maintaining 30–60% of normal activity.
Routine prophylaxis
Intravenous (Adults and Children ≥12 yr) 20–50 IU/kg three times weekly or 20–40 IU/kg every other day.
Intravenous (Children <12 yr) 25–60 IU/kg three times weekly or 25–50 IU/kg every other day.


Lyophilized powder for injection(requires reconstitution): 250 IU single use vial, 500 IU single use vial, 1000 IU single use vial, 1500 IU single use vial, 2000 IU single use vial, 3000 IU single use vial

Nursing implications

Nursing assessment

  • Monitor for signs and symptoms of hypersensitivity reactions or anaphylaxis (angioedema, chest tightness, dyspnea, wheezing, urticaria, pruritus). Discontinue Immediately and symptomatic treatment.
  • Lab Test Considerations: Monitor plasma factor VIII activity levels by one-stage clotting assay or chromogenic substrate assay to confirm adequate factor VIII levels have been achieved and maintained, when clinically indicated.
    • Monitor patients for development of inhibitors. If expected plasma levels of factor VIII activity are not attained, or if bleeding is not controlled with appropriate dose, test for factor VIII inhibitors. Determine inhibitor levels in Bethesda Units.

Potential Nursing Diagnoses

Ineffective tissue perfusion (Indications)


  • Accidental needle stick with a needle contaminated with blood can transmit infectious viruses including HIV (AIDS) and hepatitis. Obtain immediate medical attention if injury occurs.
  • Turcoctocog alfa can be infused at a hemophilia treatment center, at a health care professional's office or in the patient's home, with training.
  • Intravenous Administration
  • Bring vial and pre-filled syringe to room temperature. Do not remove the vial adapter from the protective cap. Reconstitute each vial witn 4 mL 0.9% NaCl. Follow manufacturer's instructions to prepare and reconstitute. Solution is clear to slightly unclear, without particles; do not administer solutions that are discolored or contain particulate matter. Invert turoctocog alfa vial and slowly draw solution into syringe. Stable at room temperature for 4 hr after reconstitution.
  • Rate: Inject slowly over 2 to 5 minutes.

Patient/Family Teaching

  • Instruct patient in correct method for self-administration and care of equipment. If a dose is missed, omit and administer next dose as scheduled. Do not stop using without consulting health care professional. Advise patient to read Patient Product Information before using and with each refill; new information may be available.
  • Caution patient to notify health care professional immediately if signs and symptoms of hypersensitivity reactions or anaphylaxis (rashes, hives, difficulty breathing, shortness of breath, wheezing, chest or throat tightness, difficulty swallowing, swelling of lips and tongue, light-headedness, dizziness, loss of consciousness, pale and cold skin, fast heart beat, low blood pressure, red or swollen face or hands) occur.
  • Advise patient to notify health care professional if lack of response occurs.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise patient to notify health care professional of treatment regimen prior to medical treatment or surgery.
  • Instruct patient to consult with health care professional prior to traveling. While traveling, patients should be advised to bring an adequate supply of turoctocog alfa based on their current treatment regimen.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Control and prevention of bleeding in patients with hemophilia A.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
During his time at Novo Nordisk, he led the strategic regulatory input for the orphan drug NovoEight all the way from phase one to phase three with five parallel MAAs and NDAs and five major approvals gained in a 15-month period.
For 2018, sales growth is expected to be 2-5% as Novoeight, N8-GP, and N9-GP should compensate for the potential losses of NovoSeven and Norditropin in the biopharmaceuticals segment, and Fiasp, Semaglutide, Saxenda, and Tresiba should compensate the potential losses of modern insulins in the diabetes segment.
M2 EQUITYBITES-March 30, 2015-Novo Nordisk introduces Novoeight in US
Novo Nordisk, a Danish pharmaceutical company, has launched its Novoeight (Antihaemophilic Factor [Recombinant]) in the United States, it was reported on Friday.
M2 PHARMA-March 30, 2015-Novo Nordisk introduces Novoeight in US
This year, the company is focusing on its continued roll out of Tresiba, but also on combination products such as Ryzodeb, which combines Tresiba with the fast-acting insulin NovoRapid and NovoEight.
M2 EQUITYBITES-December 9, 2014-Novo Nordisk reveals new analysis from phase III trial of NovoEight in patients with haemophilia A
Novo Nordisk, a global healthcare company, has revealed a new analysis of phase three data demonstrating that patients with haemophilia A who had the highest annualised bleeding rate during initial treatment with NovoEight (turoctocog alfa) indicated the largest reduction in bleeding over the duration of treatment, it was reported yesterday.
M2 PHARMA-December 9, 2014-Novo Nordisk reveals new analysis from phase III trial of NovoEight in patients with haemophilia A